

Global Acinetobacter Infections Treatment Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

<https://marketpublishers.com/r/GB9BA6C5240FEN.html>

Date: April 2024

Pages: 194

Price: US\$ 4,250.00 (Single User License)

ID: GB9BA6C5240FEN

Abstracts

Summary

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

According to APO Research, The global Acinetobacter Infections Treatment market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period

of 2025 through 2030.

The China market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Acinetobacter Infections Treatment is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Acinetobacter Infections Treatment include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, LegoChem Biosciences, Atterx Biotherapeutics and Achaogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Acinetobacter Infections Treatment, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Acinetobacter Infections Treatment, also provides the value of main regions and countries. Of the upcoming market potential for Acinetobacter Infections Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Acinetobacter Infections Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Acinetobacter Infections Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook

for the global Acinetobacter Infections Treatment company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Acinetobacter Infections Treatment segment by Company

Entasis Therapeutics

Roche

Adenium Biotech

Vaxdyn

Hsiri Therapeutics

Aridis Pharmaceuticals

LegoChem Biosciences

Atterx Biotherapeutics

Achaogen

Peptilogics

Sealife PHARMA

Shionogi

Techulon

Tetraphase Pharmaceuticals

Acinetobacter Infections Treatment segment by Type

Sulbactam

Carbapenems

Aminoglycosides

Polymyxins

Tetracyclines

Others

Acinetobacter Infections Treatment segment by Pipeline

ETX2514

Nacubactam RG6080

Arenicin

VXD-001

Small Molecule Antibiotic

AR-401 mAB

LCB01-0371 (PO)

GN-4474

Antibacterial Antibody

Others

Acinetobacter Infections Treatment segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Acinetobacter Infections Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Acinetobacter Infections Treatment key companies, revenue, market share, and recent developments.
3. To split the Acinetobacter Infections Treatment breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Acinetobacter Infections Treatment market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Acinetobacter Infections Treatment significant trends, drivers, influence factors in global and regions.
6. To analyze Acinetobacter Infections Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acinetobacter Infections Treatment market, and introduces in detail the market share, industry ranking,

competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acinetobacter Infections Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acinetobacter Infections Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acinetobacter Infections Treatment industry.

Chapter 3: Detailed analysis of Acinetobacter Infections Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acinetobacter Infections Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acinetobacter Infections Treatment in country level. It provides sigma data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Global Acinetobacter Infections Treatment Market Size, 2019 VS 2023 VS 2030
- 1.3 Global Acinetobacter Infections Treatment Market Size (2019-2030)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives

2 ACINETOBACTER INFECTIONS TREATMENT MARKET DYNAMICS

- 2.1 Acinetobacter Infections Treatment Industry Trends
- 2.2 Acinetobacter Infections Treatment Industry Drivers
- 2.3 Acinetobacter Infections Treatment Industry Opportunities and Challenges
- 2.4 Acinetobacter Infections Treatment Industry Restraints

3 ACINETOBACTER INFECTIONS TREATMENT MARKET BY COMPANY

- 3.1 Global Acinetobacter Infections Treatment Company Revenue Ranking in 2023
- 3.2 Global Acinetobacter Infections Treatment Revenue by Company (2019-2024)
- 3.3 Global Acinetobacter Infections Treatment Company Ranking, 2022 VS 2023 VS 2024
- 3.4 Global Acinetobacter Infections Treatment Company Manufacturing Base & Headquarters
- 3.5 Global Acinetobacter Infections Treatment Company, Product Type & Application
- 3.6 Global Acinetobacter Infections Treatment Company Commercialization Time
- 3.7 Market Competitive Analysis
 - 3.7.1 Global Acinetobacter Infections Treatment Market CR5 and HHI
 - 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
 - 3.7.3 2023 Acinetobacter Infections Treatment Tier 1, Tier 2, and Tier
- 3.8 Mergers & Acquisitions, Expansion

4 ACINETOBACTER INFECTIONS TREATMENT MARKET BY TYPE

- 4.1 Acinetobacter Infections Treatment Type Introduction
 - 4.1.1 Sulbactam
 - 4.1.2 Carbapenems
 - 4.1.3 Aminoglycosides

4.1.4 Polymyxins

4.1.5 Tetracyclines

4.1.6 Others

4.2 Global Acinetobacter Infections Treatment Sales Value by Type

4.2.1 Global Acinetobacter Infections Treatment Sales Value by Type (2019 VS 2023 VS 2030)

4.2.2 Global Acinetobacter Infections Treatment Sales Value by Type (2019-2030)

4.2.3 Global Acinetobacter Infections Treatment Sales Value Share by Type (2019-2030)

5 ACINETOBACTER INFECTIONS TREATMENT MARKET BY APPLICATION

5.1 Acinetobacter Infections Treatment Application Introduction

5.1.1 ETX2514

5.1.2 Nacubactam RG6080

5.1.3 Arenicin

5.1.4 VXD-001

5.1.5 Small Molecule Antibiotic

5.1.6 AR-401 mAB

5.1.7 LCB01-0371 (PO)

5.1.8 GN-4474

5.1.9 Antibacterial Antibody

5.1.10 Others

5.2 Global Acinetobacter Infections Treatment Sales Value by Application

5.2.1 Global Acinetobacter Infections Treatment Sales Value by Application (2019 VS 2023 VS 2030)

5.2.2 Global Acinetobacter Infections Treatment Sales Value by Application (2019-2030)

5.2.3 Global Acinetobacter Infections Treatment Sales Value Share by Application (2019-2030)

6 ACINETOBACTER INFECTIONS TREATMENT MARKET BY REGION

6.1 Global Acinetobacter Infections Treatment Sales Value by Region: 2019 VS 2023 VS 2030

6.2 Global Acinetobacter Infections Treatment Sales Value by Region (2019-2030)

6.2.1 Global Acinetobacter Infections Treatment Sales Value by Region: 2019-2024

6.2.2 Global Acinetobacter Infections Treatment Sales Value by Region (2025-2030)

6.3 North America

- 6.3.1 North America Acinetobacter Infections Treatment Sales Value (2019-2030)
- 6.3.2 North America Acinetobacter Infections Treatment Sales Value Share by Country, 2023 VS 2030
- 6.4 Europe
 - 6.4.1 Europe Acinetobacter Infections Treatment Sales Value (2019-2030)
 - 6.4.2 Europe Acinetobacter Infections Treatment Sales Value Share by Country, 2023 VS 2030
- 6.5 Asia-Pacific
 - 6.5.1 Asia-Pacific Acinetobacter Infections Treatment Sales Value (2019-2030)
 - 6.5.2 Asia-Pacific Acinetobacter Infections Treatment Sales Value Share by Country, 2023 VS 2030
- 6.6 Latin America
 - 6.6.1 Latin America Acinetobacter Infections Treatment Sales Value (2019-2030)
 - 6.6.2 Latin America Acinetobacter Infections Treatment Sales Value Share by Country, 2023 VS 2030
- 6.7 Middle East & Africa
 - 6.7.1 Middle East & Africa Acinetobacter Infections Treatment Sales Value (2019-2030)
 - 6.7.2 Middle East & Africa Acinetobacter Infections Treatment Sales Value Share by Country, 2023 VS 2030

7 ACINETOBACTER INFECTIONS TREATMENT MARKET BY COUNTRY

- 7.1 Global Acinetobacter Infections Treatment Sales Value by Country: 2019 VS 2023 VS 2030
- 7.2 Global Acinetobacter Infections Treatment Sales Value by Country (2019-2030)
 - 7.2.1 Global Acinetobacter Infections Treatment Sales Value by Country (2019-2024)
 - 7.2.2 Global Acinetobacter Infections Treatment Sales Value by Country (2025-2030)
- 7.3 USA
 - 7.3.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)
 - 7.3.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030
 - 7.3.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030
- 7.4 Canada
 - 7.4.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)
 - 7.4.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030
 - 7.4.3 Global Acinetobacter Infections Treatment Sales Value Share by Application,

2023 VS 2030

7.5 Germany

7.5.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.5.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.5.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.6 France

7.6.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.6.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.6.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.7 U.K.

7.7.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.7.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.7.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.8 Italy

7.8.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.8.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.8.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.9 Netherlands

7.9.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.9.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.9.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.10 Nordic Countries

7.10.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.10.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.10.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.11 China

7.11.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.11.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.11.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.12 Japan

7.12.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.12.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.12.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.13 South Korea

7.13.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.13.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.13.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.14 Southeast Asia

7.14.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.14.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.14.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.15 India

7.15.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.15.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.15.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.16 Australia

7.16.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.16.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.16.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.17 Mexico

7.17.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.17.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.17.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.18 Brazil

7.18.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.18.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.18.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.19 Turkey

7.19.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.19.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.19.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.20 Saudi Arabia

7.20.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.20.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.20.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

7.21 UAE

7.21.1 Global Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030)

7.21.2 Global Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030

7.21.3 Global Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030

8 COMPANY PROFILES

8.1 Entasis Therapeutics

8.1.1 Entasis Therapeutics Company Information

8.1.2 Entasis Therapeutics Business Overview

8.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio

8.1.5 Entasis Therapeutics Recent Developments

8.2 Roche

8.2.1 Roche Company Information

8.2.2 Roche Business Overview

8.2.3 Roche Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.2.4 Roche Acinetobacter Infections Treatment Product Portfolio

8.2.5 Roche Recent Developments

8.3 Adenium Biotech

8.3.1 Adenium Biotech Company Information

8.3.2 Adenium Biotech Business Overview

8.3.3 Adenium Biotech Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.3.4 Adenium Biotech Acinetobacter Infections Treatment Product Portfolio

8.3.5 Adenium Biotech Recent Developments

8.4 Vaxdyn

8.4.1 Vaxdyn Company Information

8.4.2 Vaxdyn Business Overview

8.4.3 Vaxdyn Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.4.4 Vaxdyn Acinetobacter Infections Treatment Product Portfolio

8.4.5 Vaxdyn Recent Developments

8.5 Hsiri Therapeutics

8.5.1 Hsiri Therapeutics Company Information

8.5.2 Hsiri Therapeutics Business Overview

8.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio

8.5.5 Hsiri Therapeutics Recent Developments

8.6 Aridis Pharmaceuticals

8.6.1 Aridis Pharmaceuticals Company Information

8.6.2 Aridis Pharmaceuticals Business Overview

8.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

8.6.5 Aridis Pharmaceuticals Recent Developments

8.7 LegoChem Biosciences

8.7.1 LegoChem Biosciences Company Information

8.7.2 LegoChem Biosciences Business Overview

8.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio

8.7.5 LegoChem Biosciences Recent Developments

8.8 Atterx Biotherapeutics

8.8.1 Atterx Biotherapeutics Company Information

8.8.2 Atterx Biotherapeutics Business Overview

8.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio

8.8.5 Atterx Biotherapeutics Recent Developments

8.9 Achaogen

8.9.1 Achaogen Company Information

8.9.2 Achaogen Business Overview

8.9.3 Achaogen Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.9.4 Achaogen Acinetobacter Infections Treatment Product Portfolio

8.9.5 Achaogen Recent Developments

8.10 Peptilogics

8.10.1 Peptilogics Company Information

8.10.2 Peptilogics Business Overview

8.10.3 Peptilogics Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.10.4 Peptilogics Acinetobacter Infections Treatment Product Portfolio

8.10.5 Peptilogics Recent Developments

8.11 Sealife PHARMA

8.11.1 Sealife PHARMA Company Information

8.11.2 Sealife PHARMA Business Overview

8.11.3 Sealife PHARMA Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.11.4 Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio

8.11.5 Sealife PHARMA Recent Developments

8.12 Shionogi

8.12.1 Shionogi Company Information

8.12.2 Shionogi Business Overview

8.12.3 Shionogi Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.12.4 Shionogi Acinetobacter Infections Treatment Product Portfolio

8.12.5 Shionogi Recent Developments

8.13 Techulon

8.13.1 Techulon Company Information

8.13.2 Techulon Business Overview

8.13.3 Techulon Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.13.4 Techulon Acinetobacter Infections Treatment Product Portfolio

8.13.5 Techulon Recent Developments

8.14 Tetrphase Pharmaceuticals

8.14.1 Tetrphase Pharmaceuticals Company Information

8.14.2 Tetrphase Pharmaceuticals Business Overview

8.14.3 Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Revenue and Gross Margin (2019-2024)

8.14.4 Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

8.14.5 Tetrphase Pharmaceuticals Recent Developments

9 CONCLUDING INSIGHTS

10 APPENDIX

10.1 Reasons for Doing This Study

10.2 Research Methodology

10.3 Research Process

10.4 Authors List of This Report

10.5 Data Source

10.5.1 Secondary Sources

10.5.2 Primary Sources

List Of Tables

LIST OF TABLES

Table 1. Acinetobacter Infections Treatment Industry Trends

Table 2. Acinetobacter Infections Treatment Industry Drivers

Table 3. Acinetobacter Infections Treatment Industry Opportunities and Challenges

Table 4. Acinetobacter Infections Treatment Industry Restraints

Table 5. Global Acinetobacter Infections Treatment Revenue by Company (US\$ Million) & (2019-2024)

Table 6. Global Acinetobacter Infections Treatment Revenue Share by Company (2019-2024)

Table 7. Global Acinetobacter Infections Treatment Company Ranking, 2022 VS 2023 VS 2024 & (US\$ Million)

Table 8. Global Acinetobacter Infections Treatment Key Company Manufacturing Base & Headquarters

Table 9. Global Acinetobacter Infections Treatment Company, Product Type & Application

Table 10. Global Acinetobacter Infections Treatment Company Commercialization Time

Table 11. Global Company Market Concentration Ratio (CR5 and HHI)

Table 12. Global Acinetobacter Infections Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)

Table 13. Mergers & Acquisitions, Expansion

Table 14. Major Companies of Sulbactam

Table 15. Major Companies of Carbapenems

Table 16. Major Companies of Aminoglycosides

Table 17. Major Companies of Polymyxins

Table 18. Major Companies of Tetracyclines

Table 19. Major Companies of Others

Table 20. Global Acinetobacter Infections Treatment Sales Value by Type 2019 VS 2023 VS 2030 (US\$ Million)

Table 21. Global Acinetobacter Infections Treatment Sales Value by Type (2019-2024) & (US\$ Million)

Table 22. Global Acinetobacter Infections Treatment Sales Value by Type (2025-2030) & (US\$ Million)

Table 23. Global Acinetobacter Infections Treatment Sales Value Share by Type (2019-2024)

Table 24. Global Acinetobacter Infections Treatment Sales Value Share by Type (2025-2030)

Table 25. Major Companies of ETX2514

Table 26. Major Companies of Nacubactam RG6080

Table 27. Major Companies of Arenicin

Table 28. Major Companies of VXD-001

Table 29. Major Companies of Small Molecule Antibiotic

Table 30. Major Companies of AR-401 mAB

Table 31. Major Companies of LCB01-0371 (PO)

Table 32. Major Companies of GN-4474

Table 33. Major Companies of Antibacterial Antibody

Table 34. Major Companies of Others

Table 35. Global Acinetobacter Infections Treatment Sales Value by Application 2019 VS 2023 VS 2030 (US\$ Million)

Table 36. Global Acinetobacter Infections Treatment Sales Value by Application (2019-2024) & (US\$ Million)

Table 37. Global Acinetobacter Infections Treatment Sales Value by Application (2025-2030) & (US\$ Million)

Table 38. Global Acinetobacter Infections Treatment Sales Value Share by Application (2019-2024)

Table 39. Global Acinetobacter Infections Treatment Sales Value Share by Application (2025-2030)

Table 40. Global Acinetobacter Infections Treatment Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Table 41. Global Acinetobacter Infections Treatment Sales Value by Region (2019-2024) & (US\$ Million)

Table 42. Global Acinetobacter Infections Treatment Sales Value Share by Region (2019-2024)

Table 43. Global Acinetobacter Infections Treatment Sales Value by Region (2025-2030) & (US\$ Million)

Table 44. Global Acinetobacter Infections Treatment Sales Value Share by Region (2025-2030)

Table 45. Global Acinetobacter Infections Treatment Sales Value by Country: 2019 VS 2023 VS 2030 (US\$ Million)

Table 46. Global Acinetobacter Infections Treatment Sales Value by Country (2019-2024) & (US\$ Million)

Table 47. Global Acinetobacter Infections Treatment Sales Value Market Share by Country (2019-2024)

Table 48. Global Acinetobacter Infections Treatment Sales Value by Country (2025-2030) & (US\$ Million)

Table 49. Global Acinetobacter Infections Treatment Sales Value Market Share by

Country (2025-2030)

Table 50. Entasis Therapeutics Company Information

Table 51. Entasis Therapeutics Business Overview

Table 52. Entasis Therapeutics Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 53. Entasis Therapeutics Acinetobacter Infections Treatment Product Portfolio

Table 54. Entasis Therapeutics Recent Development

Table 55. Roche Company Information

Table 56. Roche Business Overview

Table 57. Roche Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 58. Roche Acinetobacter Infections Treatment Product Portfolio

Table 59. Roche Recent Development

Table 60. Adenium Biotech Company Information

Table 61. Adenium Biotech Business Overview

Table 62. Adenium Biotech Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 63. Adenium Biotech Acinetobacter Infections Treatment Product Portfolio

Table 64. Adenium Biotech Recent Development

Table 65. Vaxdyn Company Information

Table 66. Vaxdyn Business Overview

Table 67. Vaxdyn Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 68. Vaxdyn Acinetobacter Infections Treatment Product Portfolio

Table 69. Vaxdyn Recent Development

Table 70. Hsiri Therapeutics Company Information

Table 71. Hsiri Therapeutics Business Overview

Table 72. Hsiri Therapeutics Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 73. Hsiri Therapeutics Acinetobacter Infections Treatment Product Portfolio

Table 74. Hsiri Therapeutics Recent Development

Table 75. Aridis Pharmaceuticals Company Information

Table 76. Aridis Pharmaceuticals Business Overview

Table 77. Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 78. Aridis Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

Table 79. Aridis Pharmaceuticals Recent Development

Table 80. LegoChem Biosciences Company Information

Table 81. LegoChem Biosciences Business Overview

Table 82. LegoChem Biosciences Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 83. LegoChem Biosciences Acinetobacter Infections Treatment Product Portfolio

Table 84. LegoChem Biosciences Recent Development

Table 85. Atterx Biotherapeutics Company Information

Table 86. Atterx Biotherapeutics Business Overview

Table 87. Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 88. Atterx Biotherapeutics Acinetobacter Infections Treatment Product Portfolio

Table 89. Atterx Biotherapeutics Recent Development

Table 90. Achaogen Company Information

Table 91. Achaogen Business Overview

Table 92. Achaogen Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 93. Achaogen Acinetobacter Infections Treatment Product Portfolio

Table 94. Achaogen Recent Development

Table 95. Peptilogics Company Information

Table 96. Peptilogics Business Overview

Table 97. Peptilogics Acinetobacter Infections Treatment Revenue (US\$ Million) and Gross Margin (2019-2024)

Table 98. Peptilogics Acinetobacter Infections Treatment Product Portfolio

Table 99. Peptilogics Recent Development

Table 100. Sealife PHARMA Company Information

Table 101. Sealife PHARMA Business Overview

Table 102. Sealife PHARMA Acinetobacter Infections Treatment Sales (Cases), Value (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 103. Sealife PHARMA Acinetobacter Infections Treatment Product Portfolio

Table 104. Sealife PHARMA Recent Development

Table 105. Shionogi Company Information

Table 106. Shionogi Business Overview

Table 107. Shionogi Acinetobacter Infections Treatment Sales (Cases), Value (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 108. Shionogi Acinetobacter Infections Treatment Product Portfolio

Table 109. Shionogi Recent Development

Table 110. Techulon Company Information

Table 111. Techulon Business Overview

Table 112. Techulon Acinetobacter Infections Treatment Sales (Cases), Value (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 113. Techulon Acinetobacter Infections Treatment Product Portfolio

Table 114. Techulon Recent Development

Table 115. Tetrphase Pharmaceuticals Company Information

Table 116. Tetrphase Pharmaceuticals Business Overview

Table 117. Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Sales (Cases), Value (US\$ Million), Price (USD/Case) and Gross Margin (2019-2024)

Table 118. Tetrphase Pharmaceuticals Acinetobacter Infections Treatment Product Portfolio

Table 119. Tetrphase Pharmaceuticals Recent Development

Table 120. Research Programs/Design for This Report

Table 121. Authors List of This Report

Table 122. Secondary Sources

Table 123. Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Acinetobacter Infections Treatment Product Picture

Figure 2. Global Acinetobacter Infections Treatment Market Size (US\$ Million), 2019 VS 2023 VS 2030

Figure 3. Global Acinetobacter Infections Treatment Market Size (2019-2030) & (US\$ Million)

Figure 4. Global Acinetobacter Infections Treatment Company Revenue Ranking in 2023 (US\$ Million)

Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US\$ Million)

Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 7. Sulbactam Picture

Figure 8. Carbapenems Picture

Figure 9. Aminoglycosides Picture

Figure 10. Polymyxins Picture

Figure 11. Tetracyclines Picture

Figure 12. Others Picture

Figure 13. Global Acinetobacter Infections Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 14. Global Acinetobacter Infections Treatment Sales Value Share 2019 VS 2023 VS 2030

Figure 15. Global Acinetobacter Infections Treatment Sales Value Share by Type (2019-2030)

Figure 16. ETX2514 Picture

Figure 17. Nacubactam RG6080 Picture

Figure 18. Arenicin Picture

Figure 19. VXD-001 Picture

Figure 20. Small Molecule Antibiotic Picture

Figure 21. AR-401 mAB Picture

Figure 22. LCB01-0371 (PO) Picture

Figure 23. GN-4474 Picture

Figure 24. Antibacterial Antibody Picture

Figure 25. Others Picture

Figure 26. Global Acinetobacter Infections Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 27. Global Acinetobacter Infections Treatment Sales Value Share 2019 VS 2023

VS 2030

Figure 28. Global Acinetobacter Infections Treatment Sales Value Share by Application (2019-2030)

Figure 29. Global Acinetobacter Infections Treatment Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)

Figure 30. Global Acinetobacter Infections Treatment Sales Value Share by Region: 2019 VS 2023 VS 2030

Figure 31. North America Acinetobacter Infections Treatment Sales Value (2019-2030) & (US\$ Million)

Figure 32. North America Acinetobacter Infections Treatment Sales Value Share by Country (%), 2023 VS 2030

Figure 33. Europe Acinetobacter Infections Treatment Sales Value (2019-2030) & (US\$ Million)

Figure 34. Europe Acinetobacter Infections Treatment Sales Value Share by Country (%), 2023 VS 2030

Figure 35. Asia-Pacific Acinetobacter Infections Treatment Sales Value (2019-2030) & (US\$ Million)

Figure 36. Asia-Pacific Acinetobacter Infections Treatment Sales Value Share by Country (%), 2023 VS 2030

Figure 37. Latin America Acinetobacter Infections Treatment Sales Value (2019-2030) & (US\$ Million)

Figure 38. Latin America Acinetobacter Infections Treatment Sales Value Share by Country (%), 2023 VS 2030

Figure 39. Middle East & Africa Acinetobacter Infections Treatment Sales Value (2019-2030) & (US\$ Million)

Figure 40. Middle East & Africa Acinetobacter Infections Treatment Sales Value Share by Country (%), 2023 VS 2030

Figure 41. USA Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 42. USA Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 43. USA Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 44. Canada Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 45. Canada Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 46. Canada Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 47. Germany Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 48. Germany Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 49. Germany Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 50. France Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 51. France Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 52. France Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 53. U.K. Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 54. U.K. Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 55. U.K. Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 56. Italy Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 57. Italy Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 58. Italy Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 59. Netherlands Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 60. Netherlands Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 61. Netherlands Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 62. Nordic Countries Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 63. Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 64. Nordic Countries Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 65. China Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 66. China Acinetobacter Infections Treatment Sales Value Share by Type, 2023

VS 2030 & (%)

Figure 67. China Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 68. Japan Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 69. Japan Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 70. Japan Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 71. South Korea Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 72. South Korea Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 73. South Korea Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 74. Southeast Asia Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 75. Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 76. Southeast Asia Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 77. India Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 78. India Acinetobacter Infections Treatment Sales Value Share by Type, 2023 VS 2030 & (%)

Figure 79. India Acinetobacter Infections Treatment Sales Value Share by Application, 2023 VS 2030 & (%)

Figure 80. Australia Acinetobacter Infections Treatment Sales Value Growth Rate (2019-2030) & (US\$ Million)

Figure 81. Australia Acinetobacter Inf

I would like to order

Product name: Global Acinetobacter Infections Treatment Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Product link: <https://marketpublishers.com/r/GB9BA6C5240FEN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB9BA6C5240FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

